Vectura Group and Propeller Health have announced that they will partner to develop a connected version of Vectura’s LOMI (lever-operated multi-dose inhaler) DPI using Propeller’s digital technology. The LOMI device, which is based on Vectura’s GyroHaler, uses blister strips to deliver up to 60 doses.
According to the announcement, discussions are underway to develop connected versions of other Vectura devices. In March 2016, Vectura announced that it would acquire Skyepharma, which will add MDI products to the company’s portfolio.
Propeller Health has already teamed with a number of other inhaled drug and device manufacturers including Boehringer Ingelheim, Aptar Pharma, and GSK to develop connected versions of various inhalers. Several versions of Propeller technology have received 510(k) clearance from the FDA, including for use with the Respimat and Diskus devices.
Vectura CEO James Ward-Lilley said, “This announcement demonstrates Vectura’s commitment to develop next generation inhalation devices that can help patients manage their respiratory diseases better. Adherence to therapy is one of the major issues driving poor maintenance management of these chronic conditions. There is increasing evidence of the value of intelligent sensor technology significantly enabling a reduction of symptoms, including exacerbations and long term healthcare utilization costs. This collaboration is a first step towards Vectura embracing a connected solution for all our devices.”
Propeller Health CEO David Van Sickle commented, “Digital health has the potential to make respiratory therapies more personal, powerful and convenient for every patient. We are excited to work with the team at Vectura to realize these benefits in a new generation of inhalers.”
Read the Vectura and Propeller Health press release.
